Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.
View Top Employees from Cereno Scientific| Website | http://www.cerenoscientific.com |
| Employees | 29 (25 on RocketReach) |
| Founded | 2012 |
| Technologies |
JavaScript,
HTML,
Twitter
+19 more
(view full list)
|
| Industry | Biotechnology, Medical, Drug Discovery, Health Care, Pharmaceuticals, Pharmaceutical |
Looking for a particular Cereno Scientific employee's phone or email?
Cereno Scientific Questions
Julia Fransson is the Director of Business Development of Cereno Scientific.
25 people are employed at Cereno Scientific.
Top Cereno Scientific Employees
-
3
-
1
-
ViewNick Oakes
Head of Pre-Clinical Development at Cereno Scientific
Goteborg, Vastra Gotaland, Sweden2 -
11
-
-
1
Related Companies
